Immunological Effects of Low-Dose IL-2 and Interferon-alpha in Cancer Patients
Author Information
Author(s): B. Fiorentino, P. Di Stefano, C. Giuliani, C. Amatetti, N. Tinaro, C. Natoli, C. Garufi, S. Iacobelli
Primary Institution: Universita' 'G. D'Annunzio'
Hypothesis
Can lower doses of IL-2 combined with interferon-alpha still induce immunologic effects in cancer patients?
Conclusion
The study found that a regimen of low-dose IL-2 and interferon-alpha can induce immunological changes in cancer patients with manageable toxicity.
Supporting Evidence
- An increase in NK and LAK activities was observed after treatment.
- Enhanced NK activity was seen in ten of twelve patients.
- Enhanced LAK activity was seen in eleven of twelve patients.
- Toxicity was limited to mild side effects in most patients.
- Three patients showed disease stabilization for at least three months.
Takeaway
Doctors tested a new treatment for cancer using lower doses of a medicine called IL-2 along with another medicine called interferon, and it helped boost the immune system without making patients too sick.
Methodology
Patients received a combination of interferon-alpha and escalating doses of IL-2 over six weeks, with evaluations of immune activity and toxicity.
Limitations
The study had a small sample size and variability in patient responses.
Participant Demographics
Patients included a mix of ages and genders with various types of cancer, all refractory to standard therapy.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website